Evidence map›Paper›PMID 23770626›Full record

ArticleClinical immunology (Orlando, Fla.)2013

Elimination of T cell reactivity to pancreatic β cells and partial preservation of β cell activity by peptide blockade of LFA-1:ICAM-1 interaction in the NOD mouse model.

Abby L Dotson, Lesya Novikova, Lisa Stehno-Bittel, Stephen H Benedict

Open access · bronzeAbstract read
In one paragraph

Article in Clinical immunology (Orlando, Fla.), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Abby L DotsonDepartment of Molecular Biosciences, University of Kansas, Lawrence, KS 66045, USA.
Lesya Novikova
Lisa Stehno-Bittel
Stephen H Benedict
University of Kansas · USUniversity of Kansas Medical Center · US

Funding

Immuno-modulatory Effects of Parenteral Nutrition After Intestinal FailureR21DK073119 · NIDDK · UNIVERSITY OF KANSAS MEDICAL CENTER · PI BENEDICT, STEPHEN H · 2006 to 2007
$286k
NIDDK NIH HHS DK073119NIDDK NIH HHS R21 DK073119
6 · The paper itself

Abstract

In insulin dependent diabetes mellitus (T1D), self-reactive T cells infiltrate pancreatic islets and induce beta cell destruction and dysregulation of blood glucose. A goal is to control only the self-reactive T cells, leaving the remainder of the T cell population free to protect the host. One approach is blockade of the second signal for T cell activation while allowing the first (antigen-specific) signal to occur. This work proposes that small peptides that block interaction of second signals delivered through the counter receptors LFA-1:ICAM-1 will induce attacking T cells (receiving the antigen signal) to become anergic or undergo apoptosis. In NOD mice, the peptides eliminated T cell reactivity against pancreatic antigens and reduced cellular infiltration into islets, which retained stronger density of insulin staining at five weeks after cessation of therapy. In in vitro studies the peptides induced nonresponsiveness during activation of T cells from mice and from human peripheral blood.

Indexed as

AgingAnimalsBlood GlucoseFemaleGene Expression RegulationHumansInsulin-Secreting CellsIntercellular Adhesion Molecule-1Lymphocyte Function-Associated Antigen-1MiceMice, Inbred NODPeptidesT-LymphocytesBlood GlucoseIntercellular Adhesion Molecule-1Lymphocyte Function-Associated Antigen-1PeptidesAutoimmunityDiabetesICAM-1:LFA-1NOD micePeptide costimulatory blockadeT cell tolerance

Identifiers

PMID23770626
PMCPMC3770271
OpenAlexW2000497487

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.